Recurrence rate-based strategy to tailor surveillance scheduling in single hepatocellular carcinoma ≤2 cm after curative therapy: Analysis of 6,105 global patients.

Authors

null

Qi-Feng Chen

Sun Yat-sen University Cancer Center, Guangzhou, China

Qi-Feng Chen , Ning Lyu , Ming Zhao

Organizations

Sun Yat-sen University Cancer Center, Guangzhou, China

Research Funding

No funding received
None.

Background: For initially diagnosed very early-stage hepatocellular carcinoma (HCC, VEH, i.e. single Hepatocellular Carcinoma ≤2 cm), surveillance after surgical resection (SR) or radiofrequency ablation (RFA) remains largely unclear. We conducted this multicenter study to explore optimal surveillance strategies and evaluate the current surveillance strategies for initially diagnosed VEH after SR/RFA to support the clinical follow-up schedule. Methods: A total of 6,105 initially diagnosed VEH patients who received SR/RFA from global centers were included. After the measurement of the recurrence rate of each month, delayed detection times for tumor recurrence of various follow-up strategies were calculated. The candidate strategies were evaluated according to the delayed detection times and the tumor volume doubling time (TVDT), and a preferable surveillance strategy was recommended. Results: The cumulative 1-, 2-, 3-, 4-, and 5-year recurrence probabilities were 12.7%, 25.9%, 35.7%, 43.7%, and 49.3%, respectively. Based on the monthly recurrence rate, programing surveillance schedules were tailored, which were more effective than current surveillance strategies under the same visits. When patients were followed up every 6 months, the delayed recurrence detection after curative treatment was expected to be 2.35 to 2.57 months. Given that 93.3% of patients did not have >TVDT with a rapid growth subtype when recurrent nodules were detected, a surveillance strategy with a 6-month interval was recommended. Conclusions: Six months of interval surveillance was conservatively supported in patients with VEH after curative therapy.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer - Local-Regional Disease

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr e16225)

DOI

10.1200/JCO.2023.41.16_suppl.e16225

Abstract #

e16225

Abstract Disclosures